INTRODUCTION
Venous thromboembolism (VTE), comprising pulmonary embolism and deep vein thrombosis (DVT), is a frequent complication of cancer and its treatment. Patients with active malignancy carry a seven-fold increased risk of developing VTE [1] . The occurrence of VTE causes significant morbidity and mortality in these patients. In fact, VTE is the second leading cause of death in oncology patients [2] . Furthermore, patients with cancer and established VTE are shown to have more advanced stages of malignancy and, consequently, poorer survival rates compared with cancer patients without VTE [3] . Treatment of VTE in this specific patient group is challenging as the underlying malignancy exposes these patients to a high risk of recurrent VTE, while at the same time cancer patients more frequently experience anticoagulant-related bleeding complications than VTE patients without cancer [4] .
Clinically manifest VTE is diagnosed in approximately 15% of all patients with malignant disease [5] . The actual prevalence of VTE among cancer patients is likely even higher when subclinical or asymptomatic VTE patients are taken into account. It is well known that patients with pulmonary embolism may commonly present with nonspecific symptoms or even remain completely asymptomatic [6] . For instance, silent pulmonary embolism is present in up to 32% of the patients diagnosed with DVT [7] . Also, pulmonary embolism is frequently diagnosed at autopsy while unsuspected ante mortem [8, 9] . The overall prevalence of pulmonary embolism identified at autopsies of cancer patients has been reported to be as high as 23% [10] . Now that computed tomography (CT) imaging techniques have evolved significantly over the past few decades, pulmonary embolism is increasingly being detected incidentally in cancer patients in whom pulmonary embolism was not clinically suspected at the time of the CT examination. To determine the clinical relevance of these incidental findings, data on the prognosis of cancer patients with incidental pulmonary embolism is of great importance. The current review describes the scope of this problem and summarizes recent studies addressing the clinical course and outcome of cancer patients with incidental pulmonary embolism.
PREVALENCE OF INCIDENTAL PULMONARY EMBOLISM IN ONCOLOGY PATIENTS
The introduction of thin-section multidetector row CT scanners with fast acquisition times has resulted in major improvement of visualization of the pulmonary vasculature, while intravenous contrast administration has been optimized. As a result, many routinely performed thoracic contrastenhanced CT examinations are now of adequate diagnostic value for the identification of pulmonary embolism. This has led to an increasing number of pulmonary embolism diagnoses incidentally found in patients who had undergone CT scanning for reasons other than suspected acute pulmonary embolism (Figs 1 and 2 ). In the general population, incidental pulmonary embolism has been reported to be diagnosed in 1.5% of all patients undergoing routine helical CT scans [11] . However, this prevalence is significantly higher among high-risk patients, including inpatients and patients with cancer; the vast majority of incidental pulmonary embolism diagnoses are made in the latter group [12] . This is not surprising, as patients with malignant disease are at high risk of developing pulmonary embolism [13] . Furthermore, oncology patients far more frequently undergo CT scanning compared with patients without cancer, for reasons including diagnosing, staging and treatment evaluation of the malignancy. In oncology patients, the reported prevalence of incidental pulmonary embolism ranges from 1.9 to 4.4% [14] [15] [16] [17] [18] . The detection of incidental pulmonary emboli may vary upon detector collimation and image reconstruction thickness used. In symptomatic patients, it has been clearly established that the introduction of multidetector CT pulmonary angiography (CTPA) has significantly improved the detection of pulmonary embolism, in particular those emboli located in the subsegmental branches of the pulmonary arteries [19] . For the detection of incidental pulmonary embolism, a recent systematic review reported a pooled prevalence of 2.0% for studies using CT scans with slice thickness at least 5 mm and 3.0% for studies in which CT scans with slice thickness less than 5 mm were used [20] . Browne et al. [16] hypothesized that systematically adapting a CTPA imaging protocol, by using 1-1.5 mm slices and optimizing the timing of the contrast delivery to the pulmonary vessels, in oncology patients undergoing routine CT examinations would improve the detection of incidental pulmonary embolism. In the 407 out of 408 enrolled patients in whom CTPA was considered adequate to detect intravascular contrast filling defects, pulmonary embolism was diagnosed in 18 (4.4%) patients. Of note, pulmonary embolism would not have been diagnosed in 39% of these patients if the CT scans were performed without a CTPA protocol.
RISK FACTORS
The increased risk of thrombosis in cancer patients is primarily attributed to the hypercoagulable state associated with malignancies, with the risk being greatest in patients with newly diagnosed malignancy [21] . Several risk factors have been identified
KEY POINTS
Incidentally diagnosed pulmonary embolism is a relatively common finding among patients with malignancy undergoing routine CT examinations.
Following a diagnosis of incidental pulmonary embolism, recurrent venous thromboembolic events may occur with a frequency that is even comparable to cancer patients with symptomatic pulmonary embolism.
Incidental pulmonary embolism has been associated with adverse survival in cancer patients.
The long-term mortality rate of patients with incidental pulmonary embolism appears to approach that of symptomatic patients.
When incidental pulmonary embolism is diagnosed, it is recommended to treat these patients similarly to patients with symptomatic pulmonary embolism.
that further predispose cancer patients to VTE, these include: older age, obesity, immobility, surgery, comorbid conditions, cancer-associated factors such as primary cancer site and cancer stage, and treatment-associated factors including the use of chemotherapy, hormone therapy and radiation therapy [22] .
Di Nisio et al. [23] performed a retrospective cohort study in cancer patients receiving chemotherapy, to characterize these patients' risk factors for incidental VTE. Out of 1921 patients, they identified 62 patients with incidental VTE, of whom 24 had pulmonary embolism. As for symptomatic VTE patients, metastatic disease, high leukocyte count and chemotherapy with platin agents were found to correlate with the occurrence of incidental VTE. Also, the majority of the incidental VTE cases were diagnosed within the first few months following initiation of chemotherapy, which has previously been recognized in patients with symptomatic VTE [24] . Although this study is limited by its small sample of patients and retrospective design, it does assume that cancer patients with incidental and symptomatic VTE share similar risk factors.
PROGNOSIS OF PATIENTS WITH INCIDENTAL PULMONARY EMBOLISM
Knowledge on the short-term and long-term prognosis of patients with incidental pulmonary embolism, in terms of the risk of recurrent VTE and mortality, is of major importance to guide clinical decision making for physicians who are now increasingly being confronted with incidentally detected pulmonary embolism.
Incidence of recurrent venous thromboembolism
As for the development of VTE, the presence of an active malignancy is an important risk factor for VTE recurrences. In cancer patients with established symptomatic VTE, the 1-year cumulative incidence of recurrent VTE was reported to be 20.7%, compared with 6.8% for VTE patients without cancer [4] . In the past decade, several trials indicated low-molecular-weight heparin (LMWH) monotherapy to be of superior efficacy compared with conventional treatment with vitamin K antagonists, for the long-term management of cancer-associated VTE [25] [26] [27] . Still, even during LMWH treatment, recurrent VTE occurs in up to 9% of the patients in the initial 6 months [26] . It would be important to know whether this strong association between cancer and recurrent VTE disease is also seen in patients with incidental pulmonary embolism. In contrast to symptomatic pulmonary embolism, however, the body of literature addressing cancer patients with incidental pulmonary embolism is scarce. Only few, small observational studies give some insight of the clinical course and outcome of these patients (Table 1) .
Browne et al. [16] retrospectively followed 18 cancer patients with incidental pulmonary embolism for a period of 6 months. Anticoagulant treatment was initiated in 17 patients and none of these treated patients developed recurrent VTE during follow-up. However, the one patient in whom anticoagulation therapy was withheld, because of a perceived high bleeding risk, was diagnosed with recurrent symptomatic pulmonary embolism 5 weeks later. In another case series of 34 cancer patients with incidental pulmonary embolism, of whom 29 patients received anticoagulant treatment, acute symptomatic recurrent pulmonary embolism was diagnosed in two patients (5.9%) [ recurrences were diagnosed and whether or not they occurred while on treatment. In a smaller study including three cancer patients with incidentally detected pulmonary embolism, no recurrent events occurred during 3 months of follow-up [29] . Gladish et al. [18] identified 16 patients with incidental pulmonary embolism by reassessing contrast-enhanced thoracic CT scans of oncology patients. In 12 of those patients, pulmonary embolism was not detected at the initial clinical CT image interpretation and those patients, thus, did not receive anticoagulation. During a variable followup period (range: 2 days to 24 months; average: 13 months), symptomatic DVT was diagnosed in one patient, whereas two patients developed asymptomatic recurrent embolic disease (DVT in one patient, pulmonary embolism and DVT in the other patient). Of the four patients in whom pulmonary embolism was initially reported, treatment was initiated in three patients. None of these patients developed recurrent events during a short follow-up period (ranging from 1 day to 3 months).
Font et al. [30 & ] prospectively followed a cohort of 340 cancer patients with VTE. In 94 patients, VTE was detected incidentally, and the majority (60%) of them had pulmonary embolism. All patients were treated with LMWH, in most of the patients indefinitely. Recurrent VTE was observed in 10 (11%) of the patients with incidental VTE and 44 (18%) of the symptomatic VTE patients (mean follow-up time: 477 days). Recurrent rates were not specified for pulmonary embolism patients separately. The 1-year cumulative risk of recurrent VTE was significantly lower for incidental (7%) than for symptomatic (18%) patients (P ¼ 0.043). In a retrospective cohort study including 51 cancer patients with incidental and 144 cancer patients with symptomatic pulmonary embolism, den Exter et al. ] did not find a difference in the 1-year cumulative risk of symptomatic recurrent VTE in the incidental pulmonary embolism group compared with the symptomatic pulmonary embolism patients (13.3 and 16.9% respectively, P ¼ 0.77). All patients included in this study received anticoagulant therapy with LMWH or vitamin K antagonists. The recurrent events in the incidental pulmonary embolism group comprised two cases of pulmonary embolism and three cases of DVT.
To summarize, these observational studies suggest that the risk of recurrent VTE for cancer patients with incidental pulmonary embolism is at least nonnegligible, or may even be as high as for those with symptomatic pulmonary embolism, even while receiving anticoagulant treatment. The natural clinical course of incidental pulmonary embolism, without anticoagulant treatment being prescribed, has too rarely been investigated to draw any meaningful conclusions.
Impact on survival
Symptomatic VTE has clearly been established as a poor prognostic marker in cancer patients, as it is associated with both short-term and long-term overall mortality [3, 21] . With an aim to assess the impact of incidental pulmonary embolism on the survival of cancer patients, O'Connell et al. [33 && ] performed a matched cohort study. Seventy patients with incidental pulmonary embolism were matched to 137 patients without VTE, in terms of age, cancer type and cancer stage. Compared with the matched control patients, patients with incidental pulmonary embolism had a hazard ratio for death of 1.51 (95% confidence interval: 1.01-1.27). Notably, the increased risk of death appeared to be driven by proximally located pulmonary embolism, as cancer patients with isolated subsegmental pulmonary embolism did not have poorer outcomes than control patients. The fact that the negative impact on survival was not significant at 2 months but became and was sustained significant at 6 months suggests that most mortality was not directly related to the initial pulmonary embolism event. This is not surprising as pulmonary embolism-related death is predominately caused by impaired right ventricular function [34] , which is unlikely to be present in patients without symptoms. The adverse impact on long-term survival in these patients is most likely caused by progression of the underlying malignancy. Given that the pulmonary embolism patients were matched to the control patients for cancer type and stage, mortality could not directly be attributed to more aggressive types of cancer or more advanced disease stages at baseline in the pulmonary embolism group. However, for patients with symptomatic VTE, it has previously been demonstrated that the occurrence of VTE was a predictor of mortality in specific types of cancer (namely, breast and lung cancer) even after adjusting for cancer stage and other variables associated with death [35, 36] . A possible explanation for this finding might be that the occurrence of VTE, reflecting the cancer-associated hypercoagulable state, is a surrogate for adverse tumor biology, which in turn increases the risk of tumor progression and adversely impacts survival [37] .
In line with the findings of the matched cohort study mentioned above, Dentali et al. [32 & ] found the 6-month mortality rate in cancer patients with asymptomatic VTE to be significantly higher compared with cancer patients in whom VTE was clinically suspected but ruled out (45 versus 27%, P ¼ 0.036). Furthermore, the mortality rate among incidental VTE patients did not differ from the rate found in cancer patients with symptomatic VTE (45 and 47.5%, respectively, P ¼ 0.75). This is in agreement with the cohort study of den Exter et al. [31 && ], who did not find a difference in the 1-year mortality risk of incidental pulmonary embolism patients (52.9%) compared with symptomatic pulmonary embolism patients (53.3%; P ¼ 0.7). The majority of the deaths (77.8%) in the incidental pulmonary embolism group were related to progressive cancer and none of the patients died of fatal (recurrent) pulmonary embolism. Consistently, Font et al. [30 & ] reported similar long-term mortality rates for incidental (71%) and symptomatic VTE patients (71%). Three patients (3.2%) in the incidental group and 13 patients (5.3%) in the symptomatic group died of fatal VTE. Finally, in a cohort of pancreatic cancer patients, the occurrence of both incidental and symptomatic VTE appeared to adversely affect 3-month survival (survival rates not specified) [38] . Of note, the majority of the incidental patients had asymptomatic visceral vein thrombosis (82%) and only a small proportion (7%) had pulmonary embolism.
ANTICOAGULANT TREATMENT
The central question for clinicians confronted with incidental pulmonary embolism is whether the initiation of anticoagulant therapy improves the prognosis of these patients. Until now, no randomized trials have evaluated anticoagulant therapy in patients with incidental pulmonary embolism. Furthermore, patients with incidental pulmonary embolism are routinely excluded from trials evaluating treatment strategies for patients with acute pulmonary embolism. Therefore, management of incidental pulmonary embolism is mainly extrapolated from clinical trials of symptomatic pulmonary embolism patients. Observational studies reveal that anticoagulant therapy is generally instituted once incidental pulmonary embolism is diagnosed [16,30 & ,31
Given that the occurrence of incidental pulmonary embolism by definition does not give symptoms, the primary objective of initiating anticoagulant therapy would be the prevention of recurrent, potentially fatal, VTE events. In this respect, the risk reduction in recurrent VTE must be carefully balanced to the risk of anticoagulant-related bleeding complications, in order to determine their clinical benefit. The risk of bleeding complications among cancer patients receiving anticoagulant therapy has been well recognized [4] . It has, however, been hypothesized, and some of the previously discussed studies may support this hypothesis, that incidental pulmonary embolism could be a harbinger of symptomatic VTE, and this may justify initiating anticoagulant treatment [40] . There is a clear need for further research addressing the riskbenefit ratio of anticoagulant therapy in patients with incidentally diagnosed pulmonary embolism. Until then, and in the absence of any data suggesting that the occurrence of incidental pulmonary embolism is harmless, the general consensus is that these patients should be treated. This has also been recommended in the latest edition of the American College of Chest Physicians guidelines, which suggests the same initial and long-term anticoagulation for incidental pulmonary embolism patients as for those with symptomatic pulmonary embolism, in particular if these patients are not at high risk of bleeding (grade 2B) [41] .
CONCLUSION
The increased prevalence of incidental pulmonary embolism diagnoses has made this a significant issue among cancer patients. With little knowledge on the prognosis of these patients, the greatest challenge for clinicians is to determine the best therapeutic approach. The lack of clinical trials and the limited number of observational studies do not allow firm treatment recommendations. However, some recent cohort studies suggest that the occurrence of incidental pulmonary embolism in cancer patients mirrors the prothrombotic state of these patients, which may be associated with both recurrent VTE and mortality. Further studies are needed to clarify the risk-benefit ratio of anticoagulant therapy in these patients. Currently, it is recommended to treat cancer patients with incidental pulmonary embolism in the same manner as those with symptomatic pulmonary embolism. This prospective study revealed that a large proportian of VTE events among cancer patients were diagnosed incidentally. Also, this study gives insight into the phycian's response to a diagnosis of incidental pulmonary embolism and the clinical outcome of these patients in terms of recurrent VTE, bleeding and mortality. 31.
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